Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVTA
CUSIPN/A
Phone415-374-7782
Debt
Debt-to-Equity Ratio0.42
Current Ratio3.75
Quick Ratio3.75
Price-To-Earnings
Trailing P/E Ratio-3.91
Forward P/E Ratio-5.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$68.22 million
Price / Sales10.72
Cash FlowN/A
Price / CashN/A
Book Value$2.30 per share
Price / Book4.60
Profitability
EPS (Most Recent Fiscal Year)($2.65)
Net Income$-123,380,000.00
Net Margins-125.03%
Return on Equity-111.27%
Return on Assets-62.26%
Miscellaneous
Employees594
Outstanding Shares69,050,000
Market Cap$687.03 million
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) released its earnings results on Tuesday, August, 7th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The medical research company had revenue of $37.31 million for the quarter, compared to analysts' expectations of $30.70 million. InVitae had a negative net margin of 125.03% and a negative return on equity of 111.27%. View InVitae's Earnings History.
When is InVitae's next earnings date?
What price target have analysts set for NVTA?
4 analysts have issued 1 year price objectives for InVitae's shares. Their predictions range from $9.00 to $15.00. On average, they anticipate InVitae's stock price to reach $11.00 in the next year. This suggests a possible upside of 3.9% from the stock's current price. View Analyst Price Targets for InVitae.
What is the consensus analysts' recommendation for InVitae?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD), Fulgent Genetics (FLGT), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX), OpGen (OPGN) and Biocept (BIOC).
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 60)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 44)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 58)
- Mr. Lee Bendekgey, Chief Operating Officer (Age 60)
- Ms. Patricia E. Dumond, Chief Accounting Officer & VP of Fin. (Age 53)
When did InVitae IPO?
(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Has InVitae been receiving favorable news coverage?
News coverage about NVTA stock has been trending somewhat positive on Monday, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. InVitae earned a news and rumor sentiment score of 0.20 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 46.22 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for InVitae.
Who are InVitae's major shareholders?
InVitae's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.11%), ARK INVESTMENT MANAGEMENT LLC (10.84%), BlackRock Inc. (7.17%), Redmile Group LLC (1.18%), Millennium Management LLC (0.78%) and Daiwa SB Investments Ltd. (0.75%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which institutional investors are selling InVitae stock?
NVTA stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC and Bard Associates Inc.. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Katherine Stueland, Patty Dumond, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Insider Buying and Selling for InVitae.
Which institutional investors are buying InVitae stock?
NVTA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., ARK Investment Management LLC, Millennium Management LLC, Private Wealth Partners LLC, Schwab Charles Investment Management Inc., Daiwa SB Investments Ltd., Renaissance Technologies LLC and Adviser Investments LLC. Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker, Geoffrey Crouse and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $10.59.
How big of a company is InVitae?
InVitae has a market capitalization of $687.03 million and generates $68.22 million in revenue each year. The medical research company earns $-123,380,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. InVitae employs 594 workers across the globe.
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NYSE NVTA)
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
